1415253-92-7

Basic information

• Product Name: (S)-4'-((5-((1-(3-isopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)-[1,1'-biphenyl]-2-carboxylic acid
• Synonyms: (S)-4'-((5-((1-(3-isopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)-[1,1'-biphenyl]-2-carboxylic acid
• CAS NO: 1415253-92-7
• Molecular Weight: 544.693
• Mol File: 1415253-92-7.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: (S)-4'-((5-((1-(3-isopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)-[1,1'-biphenyl]-2-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-4'-((5-((1-(3-isopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)-[1,1'-biphenyl]-2-carboxylic acid(1415253-92-7)
• EPA Substance Registry System: (S)-4'-((5-((1-(3-isopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)-[1,1'-biphenyl]-2-carboxylic acid(1415253-92-7)

Safety Data

• Hazardous Substances Data: 1415253-92-7(Hazardous Substances Data)

Upstream product

• 34246-57-6 3-isopropylbenzaldehyde 
• 1415257-91-8 (S)-1-(3-isopropylphenyl)ethan-1-amine hydrochloride 
• 1415256-97-1 (S)-tert-butyl 4'-((5-((1-(3-isopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)-[1,1'-biphenyl]-2-carboxylate 
• 619-67-0 4-Hydrazinobenzoic acid 
• 14844-73-6 2,3-dimethyl-1H-indole-5-carboxylic acid 
• 1266458-65-4 allyl 2,3-dimethyl-1H-indole-5-carboxylate 
• 1415256-20-0 1-((2'-(tert-butoxycarbonyl)biphenyl-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid 

Downstream Products

• 1415255-72-9 (S)-1-((2'-(hydroxycarbamoyl)-[1,1'-biphenyl]-4-yl)methyl)-N-(1-(3-isopropyl phenyl)ethyl)-2,3-dimethyl-1H-indole-5-carboxamide 
• 1415256-19-7 (S)-1-((2'-carbamoyl-[1,1'-biphenyl]-4-yl)methyl)-N-(1-(3-isopropylphenyl)ethyl)-2,3-dimethyl-1H-indole-5-carboxamide 
• 1415257-75-8 (S)-1-((2'-(((tert-butyldimethylsilyl)oxy)carbamoyl)-[1,1'-biphenyl]-4-yl)methyl)-N-(1-(3-isopropylphenyl)ethyl)-2,3-dimethyl-1H-indole-5-carboxamide 
• 1415255-01-4 (S)-N-(1-(3-isopropylphenyl)ethyl)-2,3-dimethyl-1-((2'-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-[1,1'-biphenyl]-4-yl)methyl)-1H-indole-5-carboxamide 
• 1415255-73-0 (S)-N-(1-(3-isopropylphenyl)ethyl)-2,3-dimethyl-1-((2’-((methylsulfonyl)carbamoyl)-[1,1‘-biphenyl]-4-yl)methyl)-1H-indole-5-carboxamide 

Relevant articles and documents

PPARG MODULATORS FOR TREATMENT OF OSTEOPOROSIS

The invention provides methods of treatment of a progressive bone disease, such as osteoporosis, Paget's Disease, multiple myeloma, or hyperparathyroidism, comprising administration of an effective amount of a non-agonist PPARG modulator to a patient afflicted with the disease.

N-BIPHENYLMETHYLINDOLE MODULATORS OF PPARG

The invention provides molecular entities that bind with high affinity to PPARG (PPAR3), inhibit kinase-mediated, e.g., cdk5-mediated, phosphorylation of PPARG, but do not exert an agonistic effect on PPARG. Compounds of the invention can be used for treatment of conditions in patients wherein PPARG plays a role, such as diabetes, insulin resistance, impaired glucose tolerance, pre-diabetes, hyperglycemia, hyperinsulinemia, obesity, or inflammation. In methods of treatment of these conditions using a compound of the invention, the compound can avoid producing side effects of significant weight gain, edema, impairment of bone growth or formation, or cardiac hypertrophy, or any combination thereof, in the patient receiving the compound. Methods of preparation of the compounds, bioassay methods for evaluating compounds of the invention as non-agonistic PPARG binding compounds, and pharmaceutical compositions are also provided.